Chinese biotech company Bio-Thera Solutions has started dosing in a phase 1 clinical trial to study the pharmacokinetics and safety of BAT2506, a proposed biosimilar of Janssen Biotech’s Simponi (golimumab).

The early-stage clinical study is a randomized two-arm, parallel-group trial that will have nearly 182 healthy volunteers. Each of the patients will be subjected to a single subcutaneous dose of BAT2506 or EU-sourced Simponi in the double-blind clinical trial.

Shengfeng Li – CEO of Bio-Thera Solutions said: “Initiating our Phase I clinical trial for BAT2506, our proposed biosimilar for Simponi, represents the fourth biosimilar that Bio-Thera has advanced into clinical trials.

“Bio-Thera is committed to bringing safe and effective biosimilars to patients around the world.”

Bio-Thera Solutions initiates phase 1 trial for Simponi biosimilar BAT2506

Headquartered in Guangzhou, Bio-Thera Solutions is engaged in developing various additional proposed biosimilars such as biosimilar versions of Avastin and Actemra/RoActemra, which are currently being investigated in global phase 3 clinical trials. The Chinese biotech company is also targeting to develop biosimilar versions of Humira and Stelara.

Related posts

• NKF to invest $95m in US generic injectables company Meitheal (0)
• Boston Scientific to be distributor of Endologix products in China (0)
• Gilead Sciences announces Biktarvy China approval for HIV-1 (0)
• Vitruvias, Sinotherapeutics launch antiarrhythmic drug Rythmol SR in US (0)
• Chinese pharma companies to evaluate combo therapy in colorectal cancer (0)
• Samsung Bioepis, C-Bridge Capital collaborate to develop and commercialize biosimilars in China (0)
• InventisBio out-licenses lung cancer drug D-0316 to Betta Pharma (0)
• Incyte, Innovent announce collaboration for three cancer drugs in China (0)
• GNI Group to stop patient enrolment in F351 phase 2 liver fibrosis trial (0)
• Five Prime, Zai Lab initiate phase 3 trial of bemarituzumab chemo combo (0)

The post Bio-Thera Solutions begins phase 1 trial for Simponi biosimilar BAT2506 appeared first on PharmaNewsDaily.com.